S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

SWTX SpringWorks Therapeutics Inc

30.94

0.32 (1.05%)

05 Nov 2024 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/03/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

02/29/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Badreddin Edris

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

SpringWorks Therapeutics (NASDAQ:SWTX)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more SpringWorks Therapeutics Charts.

SpringWorks Therapeutics (NASDAQ:SWTX)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more SpringWorks Therapeutics Charts.

SpringWorks Therapeutics Inc News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Saturday 26 October 2024 (1 week ago) • Edgar (US Regulatory)

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Tuesday 22 October 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 4 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 5 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 4 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 4 September 2024 (2 months ago) • Edgar (US Regulatory)

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
Wednesday 28 August 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 7 August 2024 (3 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 7 August 2024 (3 months ago) • Edgar (US Regulatory)

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Wednesday 7 August 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 31 July 2024 (3 months ago) • Edgar (US Regulatory)

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
Monday 29 July 2024 (3 months ago) • GlobeNewswire Inc.

More SpringWorks Therapeutics Inc News Articles

GRIID Infrastructure

EFG International Zueric... (PK)

Vox Valor Capital

Metropolis of Lyon 0.376...

Global Clean Energy (PK)

ParkerVision (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions